Tom is a co-founder and Executive Chair of ThirtyFiveBio and brings over 25 years of experience in drug discovery, development and commercialization to the team. ThirtyFiveBio was created and incubated within M:M Bio Limited (Molecule 2 Medicine), a U.K.-based biotechnology hub that leverages its unique ecosystem to build enduring, commercially orientated drug discovery and development companies. Tom is co-founder and chair of M:M Bio and also co-founder and Executive Chair of two additional biotechnology companies that are part of the overall M:M Bio hub; Grey Wolf Therapeutics and Pathios Therapeutics. His additional roles include Chair of Orbit Discovery and Venture Partner at Brandon Capital. Prior to his leadership positions within the M:M Bio ecosystem, he was President and CEO of Spinifex Pharmaceuticals, a private VC backed US/Australian biotech company developing first in class treatments for chronic pain, devoid of central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in 2015 for approximately US$700 million. Previous positions include Vice President of Drug Development at Starpharma Holdings Limited (Australia). He holds BSc (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.